Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE SME |
| SME IPO Issue Type | Fixed Price Issue |
| Total Issue Size | ₹35.34 Cr |
| Reserved for Market Maker | ₹0.00 Cr |
| Net Issue Size | ₹35.34 Cr |
| Fresh Issue | ₹33.57 Cr |
| Face Value | ₹10 Per Equity Share |
| Issue Price | ₹101.00 per share |
| Discount | Retail: 0.00 |
| BSE Code | 543616 |
| Registrar | MUFG Intime India Pvt.Ltd. |
| Lead Managers | Beeline Capital Advisors Pvt.Ltd. |
| Allotment Status |
| DRHP |
| RHP |
| Final Prospectus |
 ₹0 A/C OpeningFree MF ₹20F&O Trade ₹0Delivery 1Cr+Customers Open Free Account → |
 ₹0 A/C Opening₹0 AMC Trading Account ₹20F&O Trade ₹20Delivery FreeIPO Apply Open Free Account → |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 1,200 shares and in multiples thereof
Incorporated in 2014, Trident Lifeline Limited is engaged in the marketing of pharmaceutical products in domestic as well as international market. The company is also engaged in distribution of pharmaceutical products through third-party distribution network.
Trident Lifeline Limited offers a wide range of pharmaceutical formulations and products manufactured on contract manufacturing under a loan licence.
Trident Lifeline product portfolio consists of 832 products, as on May 31, 2022, including Anti Bacterial, Anti Diarrheal, Anti Fungal, Anti Malerial, Anti Diabetic, Dental Cure, Proton Pump Inhibitor, Anti Protozol, Anti Histamine, Anti Hypertensive drugs, Anti Lipidemic Drug, Anti Parasitic, Multivitamin, Multimineral Nyteraceutical and Non-steroidal anti-inflammatory drug (NSAIDs).
Trident Lifeline core business categories:
1. Ethical marketing of pharmaceutical formulation & products in the International Market through a third-party distribution network and sales force under its brand.
2. Getting the approved formulations manufactured through Contract Manufacturers, Source & Supply of Generic Pharma formulation and medicines in Domestic as well as International Market.
The company operate in India as well as African, Latin American and East Indian Countries. The company have a presence through registered products or products under registration in countries like Bolivia, Cambodia, Cameroon, Chile, Ghana, Kenya, Myanmar, Nigeria, Peru, Sudan, Tajikistan, Uzbekistan, and Venuzela.
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | To Meet Working Capital Requirements | 20.50 |
| 2 | Product registration in the International Markets | 5.14 |
| 3 | General Corporate Purpose | 6.71 |
| 4 | Public Issue Expenses | 3.00 |
| Period Ended | 31 Mar 2022 | 31 Mar 2021 | 31 Mar 2020 |
|---|---|---|---|
| Assets | 13.86 | 11.44 | 6.39 |
| Total Income | 22.37 | 9.78 | 5.01 |
| Profit After Tax | 2.27 | 0.63 | -0.80 |
| NET Worth | 4.80 | -0.47 | -3.00 |
| Amount in ₹ Crore | |||
| KPI | |
|---|---|
| RoNW | 47.33% |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 3.98 | |
| P/E (x) | 51.53 | |
| Promoter Holding | 100% | 69.57% |
| Market Cap | ₹116.14 Cr. | |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Lead Manger Fees including Underwriting Commission, brokerage and Selling & Marketing commission | 2.72 |
| 2 | Fees Payable to Registrar to the Issue | 0.01 |
| 3 | Fees Payable Advertising, Marketing Expenses and Printing Expenses | 0.14 |
| 4 | Fees Payable to Regulators including Stock Exchanges and other Intermediaries | 0.06 |
| 5 | Fees payable to Peer Review Auditor | 0.01 |
| 6 | Fees Payable to Market Maker (for Two Years) | 0.06 |
| 7 | Escrow Bank Fees | 0.01 |
Last Updated on 13-May-2026 10:31:38
